GSA Capital Partners LLP Has $1.20 Million Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

GSA Capital Partners LLP cut its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 60.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 449,129 shares of the biopharmaceutical company’s stock after selling 679,020 shares during the period. GSA Capital Partners LLP owned approximately 0.24% of Esperion Therapeutics worth $1,204,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in ESPR. Boomfish Wealth Group LLC bought a new stake in Esperion Therapeutics during the 1st quarter worth approximately $80,000. Mesirow Financial Investment Management Inc. purchased a new stake in Esperion Therapeutics in the 1st quarter valued at $54,000. Summit Financial LLC raised its position in Esperion Therapeutics by 66.8% in the 1st quarter. Summit Financial LLC now owns 25,864 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 10,355 shares during the last quarter. Simplicity Wealth LLC bought a new position in Esperion Therapeutics during the 1st quarter valued at $44,000. Finally, Herbst Group LLC purchased a new position in Esperion Therapeutics during the 1st quarter worth $28,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on ESPR. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Friday, June 28th. Bank of America downgraded Esperion Therapeutics from a “neutral” rating to an “underperform” rating and decreased their price target for the company from $2.90 to $2.50 in a research report on Thursday, June 20th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Esperion Therapeutics in a research report on Friday, June 28th. Finally, StockNews.com downgraded Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $8.83.

Esperion Therapeutics Stock Performance

Shares of NASDAQ ESPR traded down $0.08 during trading hours on Wednesday, reaching $2.39. 2,300,931 shares of the stock traded hands, compared to its average volume of 7,587,367. The company’s 50-day simple moving average is $2.37 and its two-hundred day simple moving average is $2.42. Esperion Therapeutics, Inc. has a 52-week low of $0.70 and a 52-week high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.34 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.42. The company had revenue of $137.74 million during the quarter, compared to analysts’ expectations of $53.11 million. On average, sell-side analysts anticipate that Esperion Therapeutics, Inc. will post 0.03 EPS for the current fiscal year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.